ReviewInternational journal of molecular sciences2021
Inflammatory Biomarkers in the Short-Term Prognosis of Venous Thromboembolism: A Narrative Review.
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 51 citations in OpenAlex.
- Ultrasound microflow imaging for the evaluation of inflammation associated with superficial vein thrombosis: a proof-of-concept case report.Quantitative imaging in medicine and surgery · 2026Article
- Malignancy as a Predictor and Potential Modifier of Laboratory Biomarker Prognostic Value in Acute Pulmonary Embolism.Diagnostics (Basel, Switzerland) · 2026Article
- Systemic Inflammation Response Index Predicts Thrombolytic Therapy Requirement in Intermediate-High Risk Acute Pulmonary Embolism: A Retrospective Study.Journal of clinical medicine · 2026Article
- Risk Stratification in Pulmonary Embolism: The Expanding Role of Biomarkers.Biomedicines · 2026Review
- Preoperative deep vein thrombosis in tibial plateau fractures: development and internal validation of an interpretable multivariable machine-learning diagnostic model.Frontiers in medicine · 2026Article
- Comparative analysis of infection-associated and non-infection-associated pulmonary embolism in children: a multicenter retrospective cohort study.Frontiers in pediatrics · 2026Article
- The Recurrence of Venous Thromboembolism in Obstructive Sleep Apnea: A Narrative Review.Canadian respiratory journal · 2025Review
- Coagulation and Inflammatory Indicators in Pneumonia Patients with Venous Thromboembolism: A Propensity-Score Matching Study.Journal of inflammation research · 2025Article
- Identification of key genes related to lymphangiogenesis in venous thromboembolism through transcriptomics and verification by RT-qPCR.Frontiers in medicine · 2025Article
- Clinical profile and long-term predictors of mortality in idiopathic acute pulmonary thromboembolism.Global cardiology science & practice · 2024Article
- Astragaloside IV induces endothelial progenitor cell angiogenesis in deep venous thrombosis through inactivation of PI3K/AKT signaling.Histology and histopathology · 2024Article
- Performance of D-dimer, cardiac troponin T, C-reactive protein, and NT-proBNP in prediction of long-term mortality in patients with suspected pulmonary embolism.European heart journal open · 2024Article
- Real-world Safety and Effectiveness of Edoxaban in Patients with Venous Thromboembolism with or without Preceding Parenteral Anticoagulants: A Single-center Retrospective Study.Internal medicine (Tokyo, Japan) · 2024Article
- The Potential Role of CA-125 as a Biomarker for Short-Term Mortality Risk in Patients with Acute Symptomatic Pulmonary Embolism.Journal of clinical medicine · 2024Article
- Article
- Use of the RCOG risk assessment model and biomarkers to evaluate the risk of postpartum venous thromboembolism.Thrombosis journal · 2023Article
- Risk factors for totally implantable access ports-associated thrombosis in pediatric oncology patients.Scientific reports · 2023Article
- Concentrations of selected acute phase proteins in patients with chronic venous insufficiency treated with Sulodexide. Part 1.Postepy dermatologii i alergologii · 2023Article
- Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: A Position Paper from the ESC Working Group on Thrombosis, in collaboration with the European Heart Rhythm Association, the Association for Acute CardioVascular Care and the Asia-Pacific Heart Rhythm Society.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2022Article
- Liquid Biopsy and Potential Liquid Biopsy-Based Biomarkers in Philadelphia-Negative Classical Myeloproliferative Neoplasms: A Systematic Review.Life (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The relationship between inflammation and venous thrombosis is not well understood. An inflammatory response may be both the cause and consequence of venous thromboembolism (VTE). In fact, several risk factors of VTE modulate thrombosis through inflammatory markers. Acute pulmonary embolism (PE) is burdened by a remarkable mortality rate, up to 34% in severely ill patients presenting with hemodynamic instability. Initial mortality risk stratification is based on hemodynamic instability. Patients with a situation of hemodynamic stability require immediate further risk assessment based on clinical, imaging, and circulating biomarkers, as well as the presence of comorbidities. Some inflammatory biomarkers have shown potential usefulness in the risk stratification of patients with VTE, especially acute PE. C-reactive protein on admission is associated with 30-day mortality and bleeding in VTE patients. P-selectin is associated with right ventricle dysfunction in PE patients and might be associated with VTE recurrences and the extension of thrombosis. Tissue factor microparticles are associated with VTE recurrence in cancer-associated thrombosis. Other inflammatory biomarkers present scarce evidence (inflammatory cytokines, erythrocyte sedimentation rate, fibrinogen, leukocyte count). In this manuscript, we will review the prognostic role of different inflammatory biomarkers available both for clinical practice and research in VTE patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.